Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

donanemab-azbt

- PMLiVE

NICE recommends Genmab’s Tivdak for recurrent or metastatic cervical cancer

It is estimated that 3,300 women are diagnosed with cervical cancer in the UK each year

- PMLiVE

Lilly to acquire LimmaTech Biologics and Vaccine Company in deals totalling $2.33bn

The acquisitions reinforce the company’s commitment to reduce the long-term burden of serious disease

- PMLiVE

Lilly and UNICEF collaborate to improve non-communicable disease prevention

Six-year initiative to improve NCD prevention and care for children in low- and middle-income countries

- PMLiVE

Lilly commits additional $4.5bn for US manufacturing sites

The company has also opened its first dedicated genetic medicine facility in Indiana in the US

- PMLiVE

Eli Lilly to acquire Kelonia Therapeutics in deal worth up to $7bn

The acquisition will help Lilly to expand its capabilities in cell and gene therapy

- PMLiVE

MHRA authorises Biogen’s higher-dose Spinraza for SMA treatment

SMA is a rare genetic neuromuscular condition affecting around 1,600 people in the UK

- PMLiVE

AC Immune amends agreement with Lilly to develop potential Alzheimer’s treatment

The agreement covers the development of new lead tau morphomer candidates

Scientist

UK clinical trial regs are changing — here’s what’s happening

Discover the transformative updates to UK clinical trial regulations, effective from April 2026, and learn how they aim to enhance transparency, participant safety, and trial efficiency.

Cuttsy + Cuttsy

- PMLiVE

Lilly to acquire Centessa in deal worth up to $7.8bn

The companies aim to advance treatments for narcolepsy and other sleep-wake disorders

- PMLiVE

Lilly’s Foundayo approved by US FDA as oral GLP-1 for weight loss

Taken at any time of the day, the oral GLP-1 is the only pill to have no food or water restrictions

- PMLiVE

MHRA approves Leqselvi for severe alopecia areata

Around 30% of patients saw 80% more scalp hair after 24 weeks of treatment

- PMLiVE

Sanofi and Regeneron’s Dupixent receives positive NICE final draft guidance for COPD

Around 1.4 million people in the UK are diagnosed with COPD, with two million thought to be undiagnosed

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links